Terns Pharmaceuticals, Inc.

NASDAQ (USD): Terns Pharmaceuticals, Inc. (TERN)

Last Price

7.08

Today's Change

+0.72 (11.32%)

Day's Change

6.38 - 7.46

Trading Volume

4,691,482

Overview

Market Cap

601 Million

Shares Outstanding

84 Million

Avg Volume

2,115,914

Avg Price (50 Days)

7.17

Avg Price (200 Days)

7.11

PE Ratio

-6.00

EPS

-1.18

Earnings Announcement

12-Mar-2025

Previous Close

6.36

Open

6.46

Day's Range

6.38 - 7.46

Year Range

4.32 - 11.4

Trading Volume

4,717,469

Price Change Highlight

1 Day Change

11.32%

5 Day Change

11.32%

1 Month Change

-0.28%

3 Month Change

-3.41%

6 Month Change

20.41%

Ytd Change

9.26%

1 Year Change

16.64%

3 Year Change

1.14%

5 Year Change

-61.50%

10 Year Change

-61.50%

Max Change

-61.50%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment